The Food and Drug Administration on Friday approved Viekira Pak, a combination of pills that becomes the fourth treatment the agency has approved to treat hepatitis C.
The indictment of 14 people Wednesday—including two pharmacists on charges of second-degree murder—was the latest in a string of actions taken in response to a deadly 2012 fungal meningitis outbreak linked to a Massachusetts compounder.
U.S. and Cuban healthcare providers could benefit from renewed U.S.-Cuban relations announced Wednesday by President Barack Obama, industry experts said. U.S. devicemakers, in particular, could soon have access to a new market hungry for its products.
A not-for-profit organization created and funded by the healthcare reform law plans to spend up to $50 million on comparative effectiveness research for hepatitis C treatments just as the government is set to approve the third drug in a new breed of treatment regimens.
A bill surfaced in the final days of the current Congress with bipartisan support to ease regulatory requirements to get drugs that treat antibiotic-resistant bacteria approved, and it is expected to also be considered by the new Congress in January.
Buried in the spending deal that congressional negotiators announced on Tuesday are several nuggets that should be of interest to hospitals, home health providers and pharmaceutical companies.
Gilead Sciences' eye-popping $1,000-a-pill cost for its hepatitis C drug Sovaldi is illegal price-gouging with the potential to bankrupt parts of the healthcare industry, according to a lawsuit filed in federal court Tuesday.
The drugmakers of three potential vaccines in development against the Ebola virus will be immune from legal liability related to their production, testing or distribution, federal officials announced Tuesday.
Merck remains committed to its $8.4 billion acquisition of Cubist Pharmaceuticals even though a federal court invalidated most of the patents protecting the company's top-selling antibiotic just hours after that deal was announced Monday.
The San Diego-based California Healthcare Institute and the San Francisco-based Bay Area Bioscience Association will merge next year to become the California Biomedical Innovation Alliance. The new organization, expected to be formed by the end of the first quarter of 2015, will represent the...
Lawyers say the suit against AstraZeneca and Ranbaxy has yielded the first jury decision in a so-called pay-for-delay case since a U.S. Supreme Court decision made it easier to challenge such agreements under federal antitrust law.
Pregnant and worried about your medication? The Food and Drug Administration is revamping those confusing labels on prescription drugs to make it easier to understand which are safe to use.